Israeli clinical-stage medical diagnostics company Check-Cap announced it is expanding its manufacturing capacity for the production of C-Scan, a colorectal cancer screening test, to support U.S. pivotal trials.
C-Scan uses an ultra-low dose x-ray capsule; an integrated positioning, control, and recording system; and proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is noninvasive and requires no sedation, the company said.
Check-Cap said it expects to launch the U.S. trials toward the end of the first quarter of 2022.
